Is all IVIG the same?
There are a number of different brands of IVIG. They differ in the details of how they are produced. In general, if you are going to be receiving IVIG on a regular basis, it may be best to use the same brand every time to reduce the risk of side effects. IVIG usually is given in a doctor’s office or hospital.
According to the report published by Allied Market Research, the global intravenous immunoglobulin market accounted for $8,995 million in 2017, and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025. The report provides a detailed analysis of changing market dynamics, top segments, value chain, key investment pockets, regional scenario, and competitive landscape.
Request Sample Report at:
https://www.alliedmarketresearch.com/request-sample/325
Based on application segment, hypogammaglobulinemia held the largest market share in 2017, and is anticipated to continue this trend in the near future. Large patient population, lack of effective substitute treatment, and early adoption of immunoglobulin for the treatment of hypogammaglobulinemia are expected to boost the growth of this segment.
Key Findings of the Intravenous Immunoglobulin (IVIG) Market:
- Myasthenia gravis segment is projected to grow at the highest rate during the forecast period.
- Hypogammaglobulinemia was the largest revenue contributor in 2017 and is expected to continue its dominance throughout the forecast period.
- North America dominated the global intravenous immunoglobulin market in 2017.
- LAMEA is estimated to grow at the highest CAGR of 10.3% from 2018-2025.
In 2017, North America accounted for the largest share in the global market, followed by Asia-Pacific. The major factors responsible for the growth of the intravenous market in these regions include high adoption rate in developed and populous countries such as Japan and the U.S. coupled with the presence of large plasma production facilities.
For Purchase Enquiry:
https://www.alliedmarketresearch.com/purchase-enquiry/325
North America to continue its dominance throughout 2022
North America occupied nearly half of the global market revenue in 2017 and is expected to retain its dominance from 2018 to 2022, owing to the high adoption rate of IVIG treatments across countries in the region supplemented with the presence of high-profile plasma production facilities. Meanwhile, LAMEA is expected to grow at the highest CAGR of 10% during the forecast period, as the region has witnessed a significant increase in the incidence of immunological & neurological diseases. The other regions analyzed in the report include Europe and Asia-Pacific.
Key market players
The key players analyzed in the report include Baxter International Inc., CSL Ltd., Grifols, S.A., Octapharma AG, Kedrion Biopharma Inc., LFB Group, Biotest AG, China Biologics Products, Inc., Shire (Baxalta), and Bayer AG. They have adopted different strategies including collaborations, joint ventures, partnerships, expansions, mergers & acquisitions, and others to gain a strong position in the industry.